801-2, Jindong Mansion, No. 536 Xueshi Road, Yinzhou, Ningbo 315100, P.R.China
Home ProductsActive Pharmaceutical Ingredients

Hepatitis C Virus Antibody API Intermediates Paritaprevir CAS 1216941-48-8

Hepatitis C Virus Antibody API Intermediates Paritaprevir CAS 1216941-48-8

Hepatitis C Virus Antibody API Intermediates Paritaprevir CAS 1216941-48-8

Product Details:

Place of Origin: China
Brand Name: Newlystar
Certification: GMP
Model Number: In - house

Payment & Shipping Terms:

Minimum Order Quantity: 10kg
Price: Negotiation
Packaging Details: tin
Delivery Time: 30days
Payment Terms: L/C, T/T
Supply Ability: one ton per month
Contact Now
Detailed Product Description
Product: Paritaprevir API CAS NO.: 1216941-48-8
Purity: NLT 98.0% Standard: In - House
Usage: Anti Hepatitis C Virus

Hepatitis C Virus Antibody API Intermediates Paritaprevir CAS 1216941-48-8

 

 

Product : Paritaprevir API

CAS: 1216941-48-8

Purity: NLT 98.0%

 

Description :

Paritaprevir is a potent inhibitor of the NS3/4A serine protease of Hepatitis C Virus (HCV). Following viral replication of HCV genetic material and translation into a single polypeptide, Nonstructural Protein 3 (NS3) and its activating cofactor Nonstructural Protein 4A (NS4A) are responsible for cleaving it into the following structural and nonstructural proteins required for assembly into mature virus: NS3, NS4A, NS4B, NS5A, and NS5B. By inhibiting viral protease NS3/4A, paritaprevir therefore prevents viral replication and function. As a newer generation and directly acting HCV antiviral, paritaprevir products have better Sustained Virological Response (SVR) rates, higher barriers to resistance, fewer side effects, and a reduced pill burden compared to older agents such as bocepravir, telaprevir, peginterferon, and ribavirin. By combining multiple antiretroviral medications into fixed dose products, the viral lifecycle can be targeted at multiple stages while simultaneously reducing the risk of developing resistant viral strains. Within Canada and the United States, paritaprevir is currently available in three fixed dose products: Viekira Pak (FDA), Technivie (FDA and Health Canada), and Holkira Pak (Health Canada). When used within the fixed dose combination product of paritaprevir/ombitasvir/ritonavir (Technivie), paritaprevir is indicated in combination with ribavirin for the treatment of patients with genotype 4 chronic hepatitis C virus (HCV) infection without cirrhosis. When used within the fixed dose combination product of paritaprevir/ombitasvir/dasabuvir/ritonavir (Viekira Pak), paritaprevir is indicated for the treatment of HCV genotype 1b without cirrhosis or with compensated cirrhosis, and when combined with ribavirin for the treatment of HCV genotype 1a without cirrhosis or with compensated cirrhosis.
 

Indication

When used within the fixed dose combination product of paritaprevir/ombitasvir/ritonavir (Technivie), paritaprevir is indicated in combination with ribavirin for the treatment of patients with genotype 4 chronic hepatitis C virus (HCV) infection without cirrhosis. When used within the fixed dose combination product of paritaprevir/ombitasvir/dasabuvir/ritonavir (Viekiera Pak), paritaprevir is indicated for the treatment of HCV genotype 1b without cirrhosis or with compensated cirrhosis, and when combined with ribavirin for the treatment of HCV genotype 1a without cirrhosis or with compensated cirrhosis.

Contact Details
Newlystar (Ningbo) Medtech Co.,Ltd.

Contact Person: Luke Liu

Send your inquiry directly to us (0 / 3000)